Micardis® in Patients With Essential Hypertension

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02187705

Enrollment

1688

Registered

2014-07-11

Start date

1999-05-31

Completion date

Unknown

Last updated

2014-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals

Interventions

DRUGTelmisartan tablets

All patients were treated with different doses of telmisartan for 14 days

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with essential hypertension * Minimum age of 18 years

Exclusion criteria

Not applicable

Design outcomes

Primary

Measure	Time frame	Description
Changes from baseline in blood pressure	Up to 14 days	Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)
Number of patients with adverse events	Up to 14 days	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026